Company Overview and News

 
GAUMONT : Résultats semestriels consolidés au 30 juin 2018

2018-09-24 globenewswire
Le Conseil d'administration de Gaumont, réuni le 20 septembre 2018 sous la présidence de Nicolas Seydoux, a arrêté les comptes au 30 juin 2018.
GAM

 
GAUMONT : Half-year consolidated results as of June 30, 2018

2018-09-24 globenewswire
The Gaumont Board of directors, which met on September 20, 2018 under the chairmanship of Nicolas Seydoux, approved the financial statements for the period ended June 30, 2018.
GAM

 
GAUMONT : Communiqué sur l'éligibilité du titre au PEA-PME

2018-04-09 globenewswire
GAUMONT SA confirme son éligibilité au PEA-PME, en respectant, sur la base des comptes au 31 décembre 2017 du Groupe, tous les critères précisés par le décret d'application n° 2014-283 du 4 mars 2014, à savoir moins de 5 000 salariés d'une part, et d'autre part un chiffre d'affaires annuel inférieur à 1,5 milliards d'euros ou un total de bilan inférieur à 2 milliards d'euros.
GAM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:GAM / GAUMONT on message board site Silicon Investor.

Computer Games Computer Games Computer Games Gamblers--can you make a living? Gamblers--can you make a living? Gamblers--can you make a living?
Casinos/Gambling and Favorite Destination Spots Casinos/Gambling and Favorite Destination Spots Casinos/Gambling and Favorite Destination Spots Penn National Gaming, Inc. (PENN) Penn National Gaming, Inc. (PENN) Penn National Gaming, Inc. (PENN)
Amaya Gaming Group Inc. Amaya Gaming Group Inc. Amaya Gaming Group Inc. TNA.V - Evergreen Gaming Corporation (Casino u0026 Restaurant) TNA.V - Evergreen Gaming Corporation (Casino u0026 Restaurant) TNA.V - Evergreen Gaming Corporation (Casino u0026 Restaurant)
Sangamo BioSciences, Inc. SGMO Sangamo BioSciences, Inc. SGMO Sangamo BioSciences, Inc. SGMO Gorilla Game Investing in the eWorld Gorilla Game Investing in the eWorld Gorilla Game Investing in the eWorld
ABC Cities Game ABC Cities Game ABC Cities Game Procter u0026 Gamble (PG) Procter u0026 Gamble (PG) Procter u0026 Gamble (PG)